
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci is a promising biotech company with a unique and efficient AI-powered platform for designing protein therapeutics. Their leading candidate ABS-201 has projected peak sales of $2.2B and their partnership with major pharmaceutical companies validates their technology in multiple therapeutic areas. Additionally, their other drug HMI-115 has potential for both endometriosis and hair growth, and their financial model is being updated to reflect the potential revenue from treating hair loss. While there are risks, the overall outlook is positive with a Buy rating and increased price target.
Bears say
Absci is heavily reliant on third-party suppliers for product manufacturing, and there is a risk of delays or disruptions in supply, which could negatively impact the company's clinical trials and potential commercialization. While the company's lead asset, ABS-201, has shown promising results in preclinical studies for conditions like androgenetic alopecia and endometriosis, there are regulatory and financial risks associated with bringing the drug to market. Additionally, there is no guarantee that ABS-201 will establish a more favorable safety and efficacy profile compared to existing treatments in these indications.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares